TherapeuticsMD (TXMD) Receivables (2010 - 2022)

TherapeuticsMD has reported Receivables for 13 years, with the latest figure at $32.2 million in Q3 2022.

• For the quarter ending Q3 2022, Receivables fell 14.02% year-over-year to $32.2 million; the trailing twelve-month figure through Sep 2022 stood at $32.2 million (down 14.02% YoY), and the FY2021 full-year result was $36.2 million, up 11.72% from the prior year.
• Receivables for Q3 2022 stood at $32.2 million, down from $45.8 million in the prior quarter.
• The five-year high for Receivables was $45.8 million in Q2 2022, with the low at $5.1 million in Q1 2018.
• Historically, Receivables has averaged $24.1 million across 5 years, with a median of $24.1 million in 2020.
• Annual changes were most pronounced in 2019 — Receivables jumped 226.75% — and 2022, when it retreated 14.02%.
• TherapeuticsMD's Receivables stood at $11.1 million in 2018, then surged by 120.5% to $24.4 million in 2019, then surged by 32.74% to $32.4 million in 2020, then grew by 11.72% to $36.2 million in 2021, then declined by 11.11% to $32.2 million in 2022.
• The last three Receivables figures came in at $32.2 million (Q3 2022), $45.8 million (Q2 2022), and $35.4 million (Q1 2022), per Business Quant data.